Improving Health-Promoting Effects of Food-Derived Bioactive Peptides Through Rational Design and Oral Delivery Strategies

Overview

Journal Nutrients

Date 2019 Oct 27

PMID 31652543

Citations 21

Authors

Paloma Manzanares

Monica Gandia

Sandra Garrigues

Jose F Marcos

Affiliations

Soon will be listed here.

Abstract

Over the last few decades, scientific interest in food-derived bioactive peptides has grown as an alternative to pharmacological treatments in the control of lifestyle-associated diseases, which represent a serious health problem worldwide. Interest has been directed towards the control of hypertension, the management of type 2 diabetes and oxidative stress. Many food-derived antihypertensive peptides act primarily by inhibiting angiotensin I-converting enzyme (ACE), and to a lesser extent, renin enzyme activities. Antidiabetic peptides mainly inhibit dipeptidyl peptidase-IV (DPP-IV) activity, whereas antioxidant peptides act through inactivation of reactive oxygen species, free radicals scavenging, chelation of pro-oxidative transition metals and promoting the activities of intracellular antioxidant enzymes. However, food-derived bioactive peptides have intrinsic weaknesses, including poor chemical and physical stability and a short circulating plasma half-life that must be addressed for their application as nutraceuticals or in functional foods. This review summarizes the application of common pharmaceutical approaches such as rational design and oral delivery strategies to improve the health-promoting effects of food-derived bioactive peptides. We review the structural requirements of antihypertensive, antidiabetic and antioxidant peptides established by integrated computational methods and provide relevant examples of effective oral delivery systems to enhance solubility, stability and permeability of bioactive peptides.

Citing Articles

Special Issue: "Rational Design and Synthesis of Bioactive Molecules".

Kostova I Int J Mol Sci. 2024; 25(18).

PMID: 39337415 PMC: 11432531. DOI: 10.3390/ijms25189927.

Exploring the impact of encapsulation on the stability and bioactivity of peptides extracted from botanical sources: trends and opportunities.

Perez-Perez V, Jimenez-Martinez C, Gonzalez-Escobar J, Corzo-Rios L Front Chem. 2024; 12:1423500.

PMID: 39050374 PMC: 11266027. DOI: 10.3389/fchem.2024.1423500.

Angiotensin-Converting Enzyme and Renin-Inhibitory Activities of Protein Hydrolysates Produced by Alcalase Hydrolysis of Peanut Protein.

Poddar S, Yu J Int J Mol Sci. 2024; 25(13).

PMID: 39000571 PMC: 11242875. DOI: 10.3390/ijms25137463.

Response Surface Modeling and Optimization of Enzymolysis Parameters for the In Vitro Antidiabetic Activities of Peanut Protein Hydrolysates Prepared Using Two Proteases.

Al-Bukhaiti W, Al-Dalali S, Noman A, Qiu S, Abed S, Qiu S Foods. 2023; 11(20).

PMID: 37431052 PMC: 9602261. DOI: 10.3390/foods11203303.

Recent advances in the development of therapeutic peptides.

Fetse J, Kandel S, Mamani U, Cheng K Trends Pharmacol Sci. 2023; 44(7):425-441.

PMID: 37246037 PMC: 10330351. DOI: 10.1016/j.tips.2023.04.003.

References

Matsui R, Honda R, Kanome M, Hagiwara A, Matsuda Y, Togitani T . Designing antioxidant peptides based on the antioxidant properties of the amino acid side-chains. Food Chem. 2017; 245:750-755. DOI: 10.1016/j.foodchem.2017.11.119. View

Auwal S, Zarei M, Tan C, Basri M, Saari N . Improved In Vivo Efficacy of Anti-Hypertensive Biopeptides Encapsulated in Chitosan Nanoparticles Fabricated by Ionotropic Gelation on Spontaneously Hypertensive Rats. Nanomaterials (Basel). 2017; 7(12). PMC: 5746911. DOI: 10.3390/nano7120421. View

Sarmadi B, Ismail A . Antioxidative peptides from food proteins: a review. Peptides. 2010; 31(10):1949-56. DOI: 10.1016/j.peptides.2010.06.020. View

Kagebayashi T, Kontani N, Yamada Y, Mizushige T, Arai T, Kino K . Novel CCK-dependent vasorelaxing dipeptide, Arg-Phe, decreases blood pressure and food intake in rodents. Mol Nutr Food Res. 2012; 56(9):1456-63. DOI: 10.1002/mnfr.201200168. View

Murray B, FitzGerald R . Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des. 2007; 13(8):773-91. DOI: 10.2174/138161207780363068. View

Renukuntla J, Vadlapudi A, Patel A, Boddu S, Mitra A . Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013; 447(1-2):75-93. PMC: 3680128. DOI: 10.1016/j.ijpharm.2013.02.030. View

Nakamura Y, Yamamoto N, Sakai K, Takano T . Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci. 1995; 78(6):1253-7. DOI: 10.3168/jds.S0022-0302(95)76745-5. View

Tyagi P, Pechenov S, Subramony J . Oral peptide delivery: Translational challenges due to physiological effects. J Control Release. 2018; 287:167-176. DOI: 10.1016/j.jconrel.2018.08.032. View

Liu R, Cheng J, Wu H . Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review. Int J Mol Sci. 2019; 20(3). PMC: 6387223. DOI: 10.3390/ijms20030463. View

10.

Ibrahim M, Bester M, Neitz A, Gaspar A . Structural properties of bioactive peptides with α-glucosidase inhibitory activity. Chem Biol Drug Des. 2017; 91(2):370-379. DOI: 10.1111/cbdd.13105. View

11.

Haller C . Nutraceuticals: has there been any progress?. Clin Pharmacol Ther. 2010; 87(2):137-41. DOI: 10.1038/clpt.2009.250. View

12.

Masuda O, Nakamura Y, Takano T . Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr. 1996; 126(12):3063-8. DOI: 10.1093/jn/126.12.3063. View

13.

Nongonierma A, FitzGerald R . Milk proteins as a source of tryptophan-containing bioactive peptides. Food Funct. 2015; 6(7):2115-27. DOI: 10.1039/c5fo00407a. View

14.

Fosgerau K, Hoffmann T . Peptide therapeutics: current status and future directions. Drug Discov Today. 2014; 20(1):122-8. DOI: 10.1016/j.drudis.2014.10.003. View

15.

Zhou Z, Cheng C, Li Y . Structure-based design and optimization of antihypertensive peptides to obtain high inhibitory potency against both renin and angiotensin I-converting enzyme. SAR QSAR Environ Res. 2015; 26(12):1001-1016. DOI: 10.1080/1062936X.2015.1104725. View

16.

Savitha M, Siddesha J, Suvilesh K, Yariswamy M, Vivek H, DSouza C . Active-site directed peptide l-Phe-d-His-l-Leu inhibits angiotensin converting enzyme activity and dexamethasone-induced hypertension in rats. Peptides. 2018; 112:34-42. DOI: 10.1016/j.peptides.2018.11.002. View

17.

FitzGerald R, Meisel H . Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr. 2001; 84 Suppl 1:S33-7. DOI: 10.1017/s0007114500002221. View

18.

Carey R, Siragy H . Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003; 24(3):261-71. DOI: 10.1210/er.2003-0001. View

19.

Garcia-Tejedor A, Sanchez-Rivera L, Castello-Ruiz M, Recio I, Salom J, Manzanares P . Novel antihypertensive lactoferrin-derived peptides produced by Kluyveromyces marxianus: gastrointestinal stability profile and in vivo angiotensin I-converting enzyme (ACE) inhibition. J Agric Food Chem. 2014; 62(7):1609-16. DOI: 10.1021/jf4053868. View

20.

Qi C, Lin G, Zhang R, Wu W . Studies on the Bioactivities of ACE-inhibitory Peptides with Phenylalanine C-terminus Using 3D-QSAR, Molecular Docking and in vitro Evaluation. Mol Inform. 2017; 36(9). DOI: 10.1002/minf.201600157. View